
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1449988/publications.pdf Version: 2024-02-01



YUKI TORISAMA

#	Article	IF	CITATIONS
1	Associations of impaired grip strength and gait function with the severity of erectile dysfunction in men undergoing dialysis: a cross-sectional study. Aging Male, 2022, 25, 1-7.	0.9	0
2	Machine learning diagnosis by immunoglobulin <i>N</i> â€glycan signatures for precision diagnosis of urological diseases. Cancer Science, 2022, 113, 2434-2445.	1.7	7
3	TMEM2 expression is downregulated as bladder cancer invades the muscle layer. Biochemical and Biophysical Research Communications, 2022, 613, 1-6.	1.0	3
4	Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with highâ€risk nonâ€muscleâ€invasive bladder cancer who receive adjuvant induction bacillus Calmetteâ€Guérin therapy. International Journal of Urology, 2022, , .	0.5	1
5	Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy. Scientific Reports, 2022, 12, .	1.6	2
6	Intraoperative upper urinary tract cytology examination is a risk factor of upper urinary tract recurrence in patients with non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 75.e9-75.e16.	0.8	0
7	Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 191.e9-191.e16.	0.8	4
8	Impact of symptomatic recurrence on oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 194.e9-194.e16.	0.8	1
9	Long-term chronological changes in urination status of patients who underwent ileal neobladder reconstruction at a single institution. International Urology and Nephrology, 2021, 53, 275-280.	0.6	0
10	The cell surface hyaluronidase TMEM2 regulates cell adhesion and migration via degradation of hyaluronan at focal adhesion sites. Journal of Biological Chemistry, 2021, 296, 100481.	1.6	24
11	<i>N</i> â€glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas. Cancer Medicine, 2021, 10, 1297-1313.	1.3	5
12	Narrative review of urinary glycan biomarkers in prostate cancer. Translational Andrology and Urology, 2021, 10, 1850-1864.	0.6	3
13	Characteristics of α2,3â€sialyl N â€glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level. Prostate, 2021, 81, 1411-1427.	1.2	8
14	The cell surface hyaluronidase TMEM2 is essential for systemic hyaluronan catabolism and turnover. Journal of Biological Chemistry, 2021, 297, 101281.	1.6	24
15	Influence of pretreatment quality of life on prognosis in patients with urothelial carcinoma. International Journal of Clinical Oncology, 2020, 25, 362-369.	1.0	3
16	Relationship between frailty and lower urinary tract symptoms among communityâ€dwelling adults. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 128-136.	0.6	31
17	Impact of the Proportion of Biopsy Positive Core in Predicting Biochemical Recurrence in Patients with Pathological Pt2 and Negative Resection Margin Status after Radical Prostatectomy. Pathology and Oncology Research, 2020, 26, 2115-2121.	0.9	2
18	Castration-resistant prostate cancer without metastasis at presentation may achieve cancer-specific survival in patients who underwent prior radical prostatectomy. International Urology and Nephrology, 2020, 52, 671-679.	0.6	9

#	Article	IF	CITATIONS
19	Serum N-glycan profiling can predict biopsy-proven graft rejection after living kidney transplantation. Clinical and Experimental Nephrology, 2020, 24, 174-184.	0.7	9
20	The Impact of Glycosylation of Osteopontin on Urinary Stone Formation. International Journal of Molecular Sciences, 2020, 21, 93.	1.8	14
21	STone Episode Prediction: Development and validation of the prediction nomogram for urolithiasis. International Journal of Urology, 2020, 27, 344-349.	0.5	5
22	Preoperative chronic kidney disease predicts poor prognosis in patients with primary non–muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 684.e1-684.e8.	0.8	4
23	Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 684.e17-684.e24.	0.8	12
24	Safety and Feasibility of Radiation Therapy to the Primary Tumor in Patients With Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2020, 18, e523-e530.	0.9	3
25	Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 795.e9-795.e17.	0.8	7
26	Sleep Disturbance Has a Higher Impact on General and Mental Quality of Life Reduction than Nocturia: Results from the Community Health Survey in Japan. European Urology Focus, 2019, 5, 1120-1126.	1.6	19
27	Clinical significance of the Lacdi NA câ€glycosylated prostateâ€specific antigen assay for prostate cancer detection. Cancer Science, 2019, 110, 2573-2589.	1.7	17
28	The Relationship Between Gait Function and Erectile Dysfunction: Results from a Community-Based Cross-Sectional Study in Japan. Journal of Sexual Medicine, 2019, 16, 1922-1929.	0.3	4
29	Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer. Scientific Reports, 2019, 9, 16761.	1.6	26
30	Relationship between oxidative stress and lower urinary tract symptoms: results from a community health survey in Japan. BJU International, 2019, 123, 877-884.	1.3	24
31	TMEM2: A missing link in hyaluronan catabolism identified?. Matrix Biology, 2019, 78-79, 139-146.	1.5	69
32	The Impact of Preoperative Severe Renal Insufficiency on Poor Postsurgical Oncological Prognosis in Patients with Urothelial Carcinoma. European Urology Focus, 2019, 5, 1066-1073.	1.6	38
33	Impact of bacillus Calmette–Guérin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Medical Oncology, 2018, 35, 41.	1.2	23
34	Oncologic outcomes for open and laparoscopic radical nephroureterectomy in patients with upper tract urothelial carcinoma. International Journal of Clinical Oncology, 2018, 23, 726-733.	1.0	24
35	Significance of preoperative butyrylcholinesterase level as an independent predictor of survival in patients with upper urinary tract urothelial carcinoma treated with nephroureterectomy. Japanese Journal of Clinical Oncology, 2018, 48, 184-189.	0.6	6
36	Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma. European Urology Focus, 2018, 4, 946-953.	1.6	70

#	Article	IF	CITATIONS
37	Significance of Serum N-glycan Profiling as a Diagnostic Biomarker in Urothelial Carcinoma. European Urology Focus, 2018, 4, 405-411.	1.6	23
38	Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava. International Journal of Clinical Oncology, 2018, 23, 134-141.	1.0	16
39	Clinical implication of a quantitative frailty assessment tool for prognosis in patients with urological cancers. Oncotarget, 2018, 9, 17396-17405.	0.8	19
40	Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institution. International Urology and Nephrology, 2018, 50, 1999-2005.	0.6	10
41	New Biomarker for Castration-Resistant Prostate Cancer: A Glycobiological Perspective. , 2018, , 307-315.		1
42	Detecting asymptomatic recurrence after radical nephroureterectomy contributes to better prognosis in patients with upper urinary tract urothelial carcinoma. Oncotarget, 2018, 9, 8746-8755.	0.8	9
43	Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma. Oncotarget, 2018, 9, 23047-23057.	0.8	9
44	A mechanism for evasion of CTL immunity by altered <i>O</i> -glycosylation of HLA class I. Journal of Biochemistry, 2017, 161, mvw096.	0.9	11
45	Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study. International Urology and Nephrology, 2017, 49, 811-816.	0.6	10
46	A mammalian homolog of the zebrafish transmembrane protein 2 (TMEM2) is the long-sought-after cell-surface hyaluronidase. Journal of Biological Chemistry, 2017, 292, 7304-7313.	1.6	125
47	Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma. International Journal of Urology, 2017, 24, 361-366.	0.5	13
48	Detecting asymptomatic recurrence after radical cystectomy contributes to better prognosis in patients with muscle-invasive bladder cancer. Medical Oncology, 2017, 34, 90.	1.2	16
49	Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma. International Journal of Clinical Oncology, 2017, 22, 366-372.	1.0	15
50	Clinical implications of serum <i>Nâ€</i> glycan profiling as a diagnostic and prognostic biomarker in germâ€cell tumors. Cancer Medicine, 2017, 6, 739-748.	1.3	23
51	The feasibility and effectiveness of robot-assisted radical cystectomy after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. Japanese Journal of Clinical Oncology, 2017, 47, 252-256.	0.6	12
52	Incidental prostate cancer in patients with muscle-invasive bladder cancer who underwent radical cystoprostatectomy. Japanese Journal of Clinical Oncology, 2017, 47, 1078-1082.	0.6	8
53	Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution. International Journal of Clinical Oncology, 2017, 22, 1087-1093.	1.0	16
54	Aortic calcification burden predicts deterioration of renal function after radical nephrectomy. BMC Urology, 2017, 17, 13.	0.6	6

Υυκι Τοβιsawa

#	Article	IF	CITATIONS
55	Clinical relevance of aortic calcification in urolithiasis patients. BMC Urology, 2017, 17, 25.	0.6	19
56	Recent progress and perspectives on prostate cancer biomarkers. International Journal of Clinical Oncology, 2017, 22, 214-221.	1.0	67
57	Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer. Oncotarget, 2017, 8, 61404-61414.	0.8	28
58	Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant. International Journal of Molecular Sciences, 2017, 18, 1731.	1.8	11
59	Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas. International Journal of Molecular Sciences, 2017, 18, 2632.	1.8	29
60	Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 261.	1.8	35
61	An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis. International Journal of Molecular Sciences, 2017, 18, 470.	1.8	37
62	The influence of serum uric acid on renal function in patients with calcium or uric acid stone: A population-based analysis. PLoS ONE, 2017, 12, e0182136.	1.1	19
63	Presence of transient hydronephrosis immediately after surgery has a limited influence on renal function 1Âyear after ileal neobladder construction. BMC Urology, 2017, 17, 72.	0.6	8
64	Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study. Oncotarget, 2017, 8, 86130-86142.	0.8	26
65	Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma. Oncotarget, 2017, 8, 49749-49756.	0.8	4
66	Risk-stratified surveillance and cost effectiveness of follow-up after radical cystectomy in patients with muscle-invasive bladder cancer. Oncotarget, 2017, 8, 65492-65505.	0.8	9
67	Preoperative chronic kidney disease predicts poor oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Oncotarget, 2017, 8, 83183-83194.	0.8	14
68	Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget, 2017, 8, 101500-101508.	0.8	50
69	Safety of heparin bridging therapy for transrectal ultrasound-guided prostate biopsy in patients requiring temporary discontinuation of antithrombotic agents. SpringerPlus, 2016, 5, 1917.	1.2	3
70	lâ€branching <i>N</i> â€acetylglucosaminyltransferase regulates prostate cancer invasiveness by enhancing α5β1 integrin signaling. Cancer Science, 2016, 107, 359-368.	1.7	22
71	Implication of aortic calcification on persistent hypertension after laparoscopic adrenalectomy in patients with primary aldosteronism. International Journal of Urology, 2016, 23, 412-417.	0.5	11
72	Core 2 β-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness. Biochemical and Biophysical Research Communications, 2016, 470, 150-156.	1.0	20

#	Article	IF	CITATIONS
73	Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy. International Journal of Clinical Oncology, 2016, 21, 379-383.	1.0	18
74	Renal Function Outcomes and Risk Factors for Risk Factors for Stage 3B Chronic Kidney Disease after Urinary Diversion in Patients with Muscle Invasive Bladder Cancer. PLoS ONE, 2016, 11, e0149544.	1.1	28
75	Slow Gait Speed and Rapid Renal Function Decline Are Risk Factors for Postoperative Delirium after Urological Surgery. PLoS ONE, 2016, 11, e0153961.	1.1	32
76	Detection of Core2 β-1,6-N-Acetylglucosaminyltransferase in Post-Digital Rectal Examination Urine Is a Reliable Indicator for Extracapsular Extension of Prostate Cancer. PLoS ONE, 2015, 10, e0138520.	1.1	19
77	Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan. BMC Urology, 2015, 15, 32.	0.6	7
78	Differences in the recurrence pattern after neoadjuvant chemotherapy compared to surgery alone in patients with muscle-invasive bladder cancer. Medical Oncology, 2015, 32, 421.	1.2	9
79	Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. International Urology and Nephrology, 2015, 47, 1509-1514.	0.6	16
80	Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis. International Journal of Clinical Oncology, 2015, 20, 1018-1025.	1.0	19
81	Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy. International Journal of Clinical Oncology, 2015, 20, 176-181.	1.0	24
82	Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer. International Journal of Clinical Oncology, 2015, 20, 369-374.	1.0	15
83	Quantification of Prostate Cancer-Associated Aberrant Glycosylation of Prostate-Specific Antigen. , 2015, , 1373-1377.		1
84	Outcome Comparison of ABO-Incompatible Kidney Transplantation With Low-Dose Rituximab and ABO-Compatible Kidney Transplantation: A Single-Center Experience. Transplantation Proceedings, 2014, 46, 445-448.	0.3	21
85	BK Virus–Associated Urothelial Carcinoma of a Ureter Graft in a Renal Transplant Recipient: A Case Report. Transplantation Proceedings, 2014, 46, 616-619.	0.3	22
86	Renal Cell Carcinoma Detected by Preoperative Kidney Transplant Donor Examination: A Case Report. Transplantation Proceedings, 2014, 46, 634-636.	0.3	0
87	Serum <i>N</i> -Glycan Alteration Associated with Renal Cell Carcinoma Detected by High Throughput Glycan Analysis. Journal of Urology, 2014, 191, 805-813.	0.2	37
88	Serum tri―and tetraâ€antennary <i>N</i> â€glycan is a potential predictive biomarker for castrationâ€resistant prostate cancer. Prostate, 2014, 74, 1521-1529.	1.2	48
89	Tubulocystic renal cell carcinoma in the left kidney: a case report. Journal of Medical Case Reports, 2014, 8, 265.	0.4	6
90	Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer. Medical Oncology, 2014, 31, 949.	1.2	27

#	Article	IF	CITATIONS
91	Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis. World Journal of Surgical Oncology, 2014, 12, 134.	0.8	5
92	Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochemical and Biophysical Research Communications, 2014, 448, 390-396.	1.0	73
93	Testicular Metastasis of Prostate Cancer: A Case Report. Case Reports in Oncology, 2014, 7, 643-647.	0.3	30
94	Blood Group Antigen-Targeting Peptide Suppresses Anti-Blood Group Antibody Binding to Antigen in Renal Glomerular Capillaries After ABO-Incompatible Blood Reperfusion. Transplantation, 2013, 95, 418-425.	0.5	7
95	Production of Hybrid-IgG/IgA Plantibodies with Neutralizing Activity against Shiga Toxin 1. PLoS ONE, 2013, 8, e80712.	1.1	16
96	Serum <i>N</i> -Glycan Profiling Predicts Prognosis in Patients Undergoing Hemodialysis. Scientific World Journal, The, 2013, 2013, 1-10.	0.8	13
97	Tumor Targeting by a Carbohydrate Ligand-Mimicking Peptide. Methods in Molecular Biology, 2013, 1022, 369-386.	0.4	6
98	Establishment of Recombinant Hybridâ€lgG / IgA Immunoglobulin Specific for Shiga Toxin. Scandinavian Journal of Immunology, 2011, 74, 574-584.	1.3	12
99	Sulfation of Colonic Mucins by N-Acetylglucosamine 6-O-Sulfotransferase-2 and Its Protective Function in Experimental Colitis in Mice. Journal of Biological Chemistry, 2010, 285, 6750-6760.	1.6	80
100	Conditional Gene Targeting in Mouse High Endothelial Venules. Journal of Immunology, 2009, 182, 5461-5468.	0.4	21
101	Influence of Local Treatments with Capsaicin or Allyl Isothiocyanate in the Sensitization Phase of a Fluorescein-Isothiocyanate-Induced Contact Sensitivity Model. International Archives of Allergy and Immunology, 2007, 143, 144-154.	0.9	25
102	Association between Aortic Calcification Burden and the Severity of Erectile Dysfunction in Men Undergoing Dialysis: A Cross-Sectional Study. World Journal of Men?s Health, 0, 40, .	1.7	0